MWI Health

MWI Health in Rapid City, South Dakota provides Spravato (esketamine), an FDA-approved nasal spray for adults living with treatment-resistant depression. By increasing glutamate and acting on the NMDA receptor, Spravato can reduce depressive symptoms far faster than conventional antidepressants, sometimes within 24 hours of the first dose.

Approved both as a monotherapy and in combination with an oral antidepressant, Spravato is also used for major depressive disorder with suicidal ideation. Treatment is supervised in the clinic, with patients monitored for at least two hours afterward and a ride home arranged beforehand.

The Rapid City office delivers Spravato alongside MWI's wider mental health services, including psychotherapy and TMS therapy, with care tailored to each patient's needs and response.